In this CGH analysis the authors show that, indeed, in breast cancer, there is amplification of the 20q and 16p regions (AURKA and PLK1) whereas the 4q region is often deleted, indicating that downregulation of MAP9 (4q32.1) could be the result, at least in part, of a gene loss. The gene discussed is PLK1; the disease is breast carcinoma.